Brandywine Oak Private Wealth LLC Has $917,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Brandywine Oak Private Wealth LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.6% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,520 shares of the medical research company’s stock after selling 58 shares during the quarter. Brandywine Oak Private Wealth LLC’s holdings in Amgen were worth $917,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Capital Performance Advisors LLP bought a new stake in Amgen in the 3rd quarter valued at about $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the third quarter valued at approximately $29,000. Matrix Trust Co acquired a new stake in Amgen during the third quarter worth approximately $36,000. Heck Capital Advisors LLC bought a new position in Amgen during the 4th quarter worth $36,000. Finally, Livelsberger Financial Advisory acquired a new position in Amgen in the 3rd quarter valued at $56,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on AMGN shares. Truist Financial reduced their target price on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Piper Sandler Companies reissued an “overweight” rating and issued a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 price target on shares of Amgen in a research report on Tuesday, October 22nd. Finally, Wolfe Research began coverage on shares of Amgen in a research report on Friday, November 15th. They set a “peer perform” rating for the company. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $314.00.

Amgen Price Performance

AMGN stock opened at $307.81 on Thursday. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a market capitalization of $165.46 billion, a P/E ratio of 39.41, a PEG ratio of 2.87 and a beta of 0.56. The company has a fifty day moving average price of $271.14 and a 200-day moving average price of $303.52.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%. As a group, equities analysts expect that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.09%. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.